9月9日，以"破浪出海 聚势共赢"为主题的深圳市福田区生物医药企业出海策略研讨会举办。活动上， 福田生物医药力量集中亮相，80余家企业、金融机构与行业协会代表共赴盛会，福田生物医药产业"出 海企业联盟"与"出海服务团"宣告启航。 本次福田区生物医药企业出海策略研讨会上，福田区医药和医疗器械出海企业联盟宣告成立，由福田区 科技和工业信息化局牵头组建的医药和医疗器械出海服务团也宣告启航，将整合政策、金融、法律、市 场等多方资源，为企业量身定制全链条出海解决方案，助力福田企业轻装上阵，开拓全球市场。 在主题分享环节，招商局集团人工智能首席科学家、狮子山人工智能实验室主任张家兴，深势科技生命 科学架构方案高级总监李夏戎，专精特新"小巨人"企业——微基因（WeGene）创始人陈钢等嘉宾，带 来了产业、技术前沿的分享，碰撞思想的火花。 出海之路，机遇与挑战并存。研讨会还邀请了多位中外行业专家，带来实战分享，送上出海"锦囊"，为 帮助企业走好出海之路。 作为深圳中心城区，福田致力打造都市型科创区，吸引了各类生物医药企业与创新资源落地生根，目前 已集聚百余家生物医药规模企业，建成国际生物医药产业园一期、二期以及河套科创中心合 ...

Group 1 - The Oman Sovereign Wealth Fund, managing $50 billion in assets, is seeking to enhance cooperation with Shenzhen in technology and finance sectors [1][2] - The meeting highlighted the complementary strengths of Oman in energy transition and infrastructure financing, and Shenzhen's advantages in artificial intelligence, new energy vehicles, and medical devices [2][3] - Oman aims to collaborate with Shenzhen in three key areas: artificial intelligence and big data, renewable energy, and enhancing efficiency in various industries through AI [2][3] Group 2 - The Oman Investment Authority is the sole sovereign wealth fund manager in Oman, focusing on managing funds for future generations and improving the investment environment [1] - The meeting included discussions on Shenzhen's business environment and investment promotion, as well as the city's policies on artificial intelligence, new energy vehicles, and medical devices [3]

中国基金报记者 郭玟君 【导读】阿曼 500亿美元主权投资基金组团到访深圳，拟加强科技与金融合作 9月2日，深圳市金融办组织到访深圳的阿曼苏丹国（以下简称 阿曼） 政府金融系统代表团，与深圳市多个政府部门及企业举行座谈会，双 方一致认为，阿曼与深圳在高科技产业及金融领域的合作空间广阔。 阿曼 政府金融系统代表团成员分别来自阿曼投资局 (OIA)、玛氏发展与投资基金(MDI)、阿曼金融服务局(FSA)、马斯喀特证券交易所 (MSX)、马斯喀特清算所(MCD)、雅宝资管(Jabal)。 座谈会上，深圳市投资促进局、深圳市商务局、深圳市贸促会相关负责人介绍了深圳市营商环境、企业出海、交流互访机制情况。深圳市 人工智能产业办、深圳市新能源汽车产业办、深圳市医药和医疗器械产业办相关负责人介绍了深圳市相关产业发展政策、科技创新成果及 对外合作意向。深创投和深圳市福田区相关负责人分别介绍了深圳市基金发展情况。 版权声明 《中国基金报》对本平台所刊载的原创内容享有著作权，未经授权禁止转载，否则将追究法律责任。 授权转载合作联系人：于先生（电话：0755-82468670） 编辑：江右 校对：乔伊 制作：小茉 审核：陈墨 据阿 ...

Group 1 - Shenzhen is positioned as a leader in China's modernization, with the new policy document aimed at deepening reform and innovation, providing valuable experience for national development [1] - The projected GDP for Shenzhen in 2024 is 3.68 trillion yuan, reflecting a year-on-year growth of 5.8%, with strategic emerging industries contributing 1.5567 trillion yuan, accounting for 42.3% of the GDP [1] - Shenzhen has established three industry offices focusing on artificial intelligence, new energy vehicles, and medical devices to accelerate development in key sectors [1] Group 2 - As of April 2025, Shenzhen has nearly 4.47 million registered business entities, a year-on-year increase of 3.5%, with approximately 2.78 million being enterprises, representing 62.2% of the total [2] - The number of newly registered foreign-funded enterprises in Shenzhen increased by 33.4% from January to April [2] - The new policy is seen as a "second acceleration" of Shenzhen's comprehensive reform pilot, emphasizing the commitment to continuous reform and openness [2]

Core Viewpoint - Shenzhen is embarking on a new exploration of innovative reform methods, as outlined in the recently published opinions by the Central Committee of the Communist Party of China and the State Council, focusing on comprehensive reform and opening up to enhance its role in the Guangdong-Hong Kong-Macao Greater Bay Area and contribute to the modernization of the country [1][2]. Group 1: Reform Initiatives - The recent opinions emphasize four key areas: integrated reform of education, technology, and talent systems; empowering the real economy through finance, technology, and data; establishing a higher-level open economy; and improving governance models [1]. - Shenzhen has seen significant reforms since the initiation of the comprehensive reform pilot in October 2020, with multiple innovative measures being promoted nationally [2][3]. Group 2: Economic Performance - In 2024, Shenzhen's GDP reached 3.68 trillion yuan, reflecting a year-on-year growth of 5.8%, with strategic emerging industries contributing 1.5567 trillion yuan, accounting for 42.3% of the GDP [4]. - The production of new energy vehicles in Shenzhen grew by 69.2%, representing 22.3% of the national total, positioning Shenzhen as the leading city in automotive production in China [4]. Group 3: Competitive Edge - Shenzhen has enhanced its competitive strength through reforms that improve the legal and business environment, including the development of innovative financial products and regulatory frameworks [5]. - The city has seen a 3.5% year-on-year increase in registered business entities, reaching nearly 4.47 million, with a notable 33.4% growth in newly registered foreign enterprises in early 2025 [5]. Group 4: Future Outlook - The ongoing reforms are expected to continuously stimulate Shenzhen's development, maintaining its rapid growth and significant contribution to the national economy, with only 0.02% of the country's land area accounting for over 2.7% of its economic output [6]. - As Shenzhen celebrates the 45th anniversary of its economic zone, it is poised to further advance in reform and innovation, leading the way in China's modernization efforts [6].

Core Viewpoint - Shenzhen's new measures aim to significantly boost the pharmaceutical and medical device industries through comprehensive support across the entire development chain [1][3]. Group 1: Policy Measures - The new policy includes 32 specific measures focusing on nine key areas: R&D innovation, AI application, clinical trials, registration and approval, production, promotion, international expansion, talent and financial empowerment, and investment promotion [1][2]. - The measures align with national and provincial requirements for supporting innovative pharmaceuticals and medical devices, covering emerging technologies and new business models such as AI-enhanced pharmaceuticals and medical devices, biomanufacturing, and gene therapy [1][2]. Group 2: AI and Biomanufacturing - The policy promotes the application of AI in biomanufacturing and pharmaceutical R&D, supporting the establishment of major public service platforms and industrial projects [2]. - It encourages collaboration between innovative companies and AI service platforms, providing financial support of up to 200 million yuan per year for contract R&D expenses [2]. Group 3: Financial Incentives - The policy offers substantial financial rewards for innovative drug development, with up to 3 million yuan available for each phase of clinical trials for first-class innovative drugs [3]. - Shenzhen's pharmaceutical industry is projected to reach nearly 55 billion yuan in output value by 2024, marking a historical high [3]. Group 4: Industry Goals - By 2025, Shenzhen aims to become a globally recognized center for innovative drug R&D, with the biopharmaceutical industry's added value reaching 40 billion yuan and total revenue hitting 100 billion yuan [3].